Vaxcyte, Inc. (PCVX) Financials
NASDAQ:PCVXMarket Cap
4.71B
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| -- | -- | -- | -- | -- | |
| -- | -- | -- | -- | -- | |
| -- | -- | -- | -- | -- | |
| 30,145,000 | 45,607,000 | 73,564,000 | 78,411,000 | 169,451,000 | |
| -- | -- | -- | -- | -- | |
| 5,388,000 | 8,546,000 | 16,017,000 | 25,259,000 | 39,810,000 | |
| 5,388,000 | 8,546,000 | 16,017,000 | 25,259,000 | 39,810,000 | |
| 35,533,000 | 53,916,000 | 87,103,000 | 102,085,000 | 207,330,000 | |
| -35,533,000 | -54,153,000 | -89,581,000 | -103,670,000 | -232,256,000 | |
| 5,220,000 | 3,879,000 | 364,000 | 3,593,000 | 8,771,000 | |
| -28,415,000 | -48,867,000 | -86,859,000 | -98,284,000 | -189,778,000 | |
| 1,037,000 | 5,286,000 | 2,722,000 | 5,386,000 | 42,478,000 | |
| 903,000 | 632,000 | 244,000 | 344,000 | 8,356,000 | |
| 75,000 | 40,000 | 7,000 | 7,000 | 2,000 | |
| -29,485,000 | -50,274,000 | -89,217,000 | -100,077,000 | -223,485,000 | |
| 6,123,000 | 3,225,000 | -1,398,000 | 7,000 | 16,155,000 | |
| -29,485,000 | -53,499,000 | -87,819,000 | -100,084,000 | -239,640,000 | |
| -1.15 | -2.09 | -2.97 | -1.93 | -3.69 | |
| -1.15 | -2.09 | -2.97 | -1.93 | -3.69 | |
| 25,598,640 | 25,598,640 | 29,545,810 | 51,922,108 | 64,877,988 | |
| 25,598,640 | 25,598,640 | 29,545,810 | 51,922,108 | 64,877,988 | |
| 35,533,000 | 53,916,000 | 87,103,000 | 102,085,000 | 207,330,000 | |
| 5,178,000 | -237,000 | -2,478,000 | -1,585,000 | -1,931,000 |
Key Facts
Industry
Biotechnology
Sector
Healthcare
Headquarters
San Carlos, CA, US
Website
CEO
Mr. Grant E. Pickering M.B.A.
Employees
158
About the Company
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.